Tyrosine kinase inhibitor for CML: all the same?
作者信息
Veltmaat Lukas, Cortes Jorge
机构信息
Medical College of Georgia, Augusta University, Augusta, GA.
Georgia Cancer Center, Augusta University, Augusta, GA.
出版信息
Blood Adv. 2024 Oct 22;8(20):5339-5341. doi: 10.1182/bloodadvances.2024014060.
Abstract
摘要
相似文献
1
Tyrosine kinase inhibitor for CML: all the same?用于慢性粒细胞白血病的酪氨酸激酶抑制剂：都一样吗？
Blood Adv. 2024 Oct 22;8(20):5339-5341. doi: 10.1182/bloodadvances.2024014060.
2
Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors.慢性粒细胞白血病（CML）：对酪氨酸激酶抑制剂的耐药性。
Ann Oncol. 2006 Sep;17 Suppl 10:x274-9. doi: 10.1093/annonc/mdl273.
3
Important therapeutic targets in chronic myelogenous leukemia.慢性髓性白血病的重要治疗靶点。
Clin Cancer Res. 2007 Feb 15;13(4):1089-97. doi: 10.1158/1078-0432.CCR-06-2147.
4
Evolution of CML treatment.慢性粒细胞白血病治疗的演变
Int J Hematol. 2021 May;113(5):622-623. doi: 10.1007/s12185-021-03128-4. Epub 2021 Mar 15.
5
Kinase inhibitors in chronic myelogenous leukemia.慢性粒细胞白血病中的激酶抑制剂
Clin Adv Hematol Oncol. 2006 May;4(5):365-74.
6
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.靶向自噬可增强酪氨酸激酶抑制剂对费城染色体阳性细胞（包括原发性慢性粒细胞白血病干细胞）的诱导细胞死亡作用。
J Clin Invest. 2009 May;119(5):1109-23. doi: 10.1172/JCI35660. Epub 2009 Apr 13.
7
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
8
Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.酪氨酸激酶抑制剂时代慢性髓性白血病晚期的管理
Leuk Lymphoma. 2009 Jan;50(1):14-23. doi: 10.1080/10428190802517765.
9
In vitro anti-leukaemia activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs).吡咯并[1,2-b][1,2,5]苯并噻二嗪（PBTDs）的体外抗白血病活性。
Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):58-68. doi: 10.2174/157489210789702163.
本文引用的文献
1
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.尼洛替尼与达沙替尼治疗初治慢性髓性白血病达到 MR4.5 ：随机 JALSG CML212 研究。
Blood Adv. 2024 Oct 22;8(20):5237-5247. doi: 10.1182/bloodadvances.2024012655.
2
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.阿西替尼治疗新诊断的慢性髓性白血病。
N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31.
3
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.博舒替尼对比伊马替尼用于初诊慢性期慢性髓性白血病：BFORE 试验的最终结果。
Leukemia. 2022 Jul;36(7):1825-1833. doi: 10.1038/s41375-022-01589-y. Epub 2022 May 28.
4
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial.低剂量达沙替尼治疗慢性期慢性髓性白血病老年患者（DAVLEC）：一项单臂、多中心、2 期临床试验。
Lancet Haematol. 2021 Dec;8(12):e902-e911. doi: 10.1016/S2352-3026(21)00333-1.
5
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.基于治疗药物监测的达沙替尼剂量优化可降低慢性髓性白血病患者胸腔积液发生率。
Br J Haematol. 2021 Jul;194(2):393-402. doi: 10.1111/bjh.17654. Epub 2021 Jun 30.
6
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.一线尼洛替尼对比伊马替尼治疗初诊慢性期慢性髓性白血病的长期疗效：ENESTnd 研究 10 年分析。
Leukemia. 2021 Feb;35(2):440-453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7.
7
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.新型慢性髓性白血病初诊患者每日接受低剂量达沙替尼（50mg）治疗的长期随访结果。
Cancer. 2020 Jan 1;126(1):67-75. doi: 10.1002/cncr.32504. Epub 2019 Sep 25.
8
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.DASISION的5年最终研究结果：达沙替尼与伊马替尼治疗初治慢性髓性白血病患者的试验
J Clin Oncol. 2016 Jul 10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899. Epub 2016 May 23.
9
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.早期分子反应和女性性别强烈预测慢性髓细胞白血病患者伊马替尼停药的标准，即 BCR-ABL1 持续不可检测。
Blood. 2013 May 9;121(19):3818-24. doi: 10.1182/blood-2012-10-462291. Epub 2013 Mar 20.
Zotero 插件